论文部分内容阅读
用血脂康胶囊治疗60例原发性高脂血症患者。经8周临床观察,结果示降总胆固醇(TC)、甘油三酯(TG),升高密度脂蛋白胆固醇(HDL-C),降(TC-HDL-C)/HDL-C的总有效率分别占95.5％、82.5％、85.4％和88.3％;平均降TC、TG、LDC-C、(TC—HDL-C)/HDL-C、升HDL-C分别为25％、35.6％、28.6％、31.2％和22.6％。各组与治疗前比较有非常显著差异(均P<0.01),提示血脂康治疗高脂血症安全有效。经8周随访,继以半量维持者,各血脂指标仍保持在较稳定的理想水平,而完全停药后,则血脂水平有回升,显示服药取得疗效后,为避免“反跳”,应以减量维持为佳。
Treatment of 60 cases of primary hyperlipidemia with Xuezhikang capsule. After 8 weeks of clinical observation, the results showed that the total effective rate of total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C) and antihypertensive (TC-HDL-C) Respectively, accounting for 95.5%, 82.5%, 85.4% and 88.3%, respectively. The mean HDL-C and TCL, TG, LDC-C and TCL were 25%, 35.6% and 28.6% , 31.2% and 22.6% respectively. Each group compared with before treatment have very significant differences (all P <0.01), suggesting Xuezhikang treatment of hyperlipidemia is safe and effective. After eight weeks of follow-up, followed by half of those who maintain, all lipid indicators remained at a more stable and ideal level, and completely stopped, the blood lipids levels rise, showing that medication to obtain efficacy, to avoid “rebound” should Reduced maintenance is better.